August 27, 2018
Gilead Sciences and Japan Tobacco are launching discussions on the possible termination of their long-standing licensing deals for HIV agents in Japan as the big biotech now has a stand-alone commercialization plan for its new HIV triplet Biktarvy (bictegravir +...read more